Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations

Ralph Epaud, Céline Delestrain, Malek Louha, Stéphanie Simon, Pascale Fanen, Abdellatif Tazi
European Respiratory Journal 2014 43: 638-641; DOI: 10.1183/09031936.00145213
Ralph Epaud
1Inserm, U955, Equipe 11, Créteil
2Université Paris-Est, UMR_S955, UPEC, Créteil
3Centre Hospitalier Intercommunal de Créteil, Service de Pédiatrie, Créteil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ralph.epaud@chicreteil.fr
Céline Delestrain
1Inserm, U955, Equipe 11, Créteil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malek Louha
4AP-HP, Hôpital Armand Trousseau, Service de Biochimie-Génétique Moléculaire, Paris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphanie Simon
1Inserm, U955, Equipe 11, Créteil
2Université Paris-Est, UMR_S955, UPEC, Créteil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascale Fanen
1Inserm, U955, Equipe 11, Créteil
2Université Paris-Est, UMR_S955, UPEC, Créteil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdellatif Tazi
5Université Paris Diderot, Paris
6INSERM UMR 717, AP-HP, Service de Pneumologie, Hôpital Saint Louis, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editor:

Herein, we present the first report of combined pulmonary fibrosis and emphysema (CPFE) in an adult patient who was compound heterozygous for mutations of the ATP-binding cassette subfamily A member 3 gene (ABCA3, MIM 601615).

A 41-year-old nonsmoking male presented with dyspnoea on mild exertion. The patient’s medical history indicated neonatal respiratory distress, gastro-oesophageal reflux and pneumonia 8 years previously that resolved with antibiotics. His physical examination revealed a mild pectus excavatum, finger clubbing and bilateral basal crackles. High-resolution computed tomography (HRCT) of the chest showed voluminous emphysema in the upper zones of the lungs associated with honeycomb fibrosis and ground-glass opacity in lower lobes, predominating in left lung (fig. 1). The bronchoalveolar lavage differential cell count was 67% macrophages, 22% neutrophils and 8% lymphocytes. Pulmonary function tests showed: total lung capacity of 75%, vital capacity (VC) of 50%, residual volume of 134%; forced expiratory volume in 1 s (FEV1) of 49%, diffusing capacity of the lung for carbon monoxide of 38% predicted, FEV1/VC of 74%, and arterial oxygen tension at room air was 96 mmHg. During a 6-min walk test the peripheral oxygen saturation decreased from 96% at rest to 90% after 630 m (80% of predicted value). A lung biopsy was not performed. Doppler echocardiography showed normal heart cavities, with estimated systolic pulmonary arterial pressure of 37 mmHg. Serum α1-antitrypsin levels, autoimmune markers (including anti-nuclear antibody and rheumatoid factor), and immunoglobulin pattern were normal.

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

High-resolution computed tomography of the chest showing a, b) left upper lobe predominant emphysema associated with a, c) ground-glass opacities and c) asymmetric honeycomb pattern in the lower zones.

This clinical presentation of CPFE in a young patient prompted us to screen mutations in genes causing surfactant dysfunction. After informed consent was obtained, sequencing analysis of the surfactant protein C gene (SFTPC, MIM 178620) revealed no mutation. Sequence analysis of the ABCA3 gene identified two mutations: 1) c.3081_3092delinsCG resulting in a serine to valine change at codon 1028 with the creation of a stop codon 103 amino acids downstream (p.Ser1028Valfs*103); and 2) the common mutation c.875A>T changing a glutamic acid to a valine at codon 292 (p.Glu292Val). None of these mutations were found in either the public polymorphism database or our controls. 2 years after presentation, chest HRCT as well as lung function worsened and azithromycin (250 mg every other day) was initiated.

Pulmonary surfactant, a complex mixture of lipids and specific proteins located at the air–liquid interface, lowers alveolar surface tension thereby preventing alveolar collapse at the end of expiration. It is synthesised by alveolar type II cells, stored in lamellar bodies, and secreted by exocytosis. ABCA3 is expressed in the lamellar bodies of alveolar type II cells and is crucial to pulmonary surfactant storage and homeostasis. Several studies indicated a role of genes involved in surfactant metabolism in the development of diffuse lung diseases [1].

CPFE is a syndrome characterised by the coexistence of emphysema and pulmonary fibrosis in the same patient [2]. It typically occurs in male smokers and is associated with dyspnoea, upper lobe emphysema, lower lobe fibrosis and abnormalities of gas exchange. In the absence of the SFTPC mutation, previously associated with CPFE [3], we decided to analyse other genes involved in surfactant metabolism, such as ABCA3. Recessive loss-of-function mutations in ABCA3 present as lethal surfactant deficiency in the newborn, whereas other recessive mutations in ABCA3 can result in interstitial lung disease in older children [4]. Previous studies showed that homozygous or compound heterozygous ABCA3 mutations led to abnormal processing and/or trafficking of the ABCA3 protein [5], alterations in ABCA3 protein functions such as ATPase activity [6], or impaired lipid transport [7]. As previously described, our patient had a less severe phenotype than is usually associated with ABCA3 mutations [4]. These variations in the clinical and radiological features may be related to the nature of the mutation. Our patient was found to be compound heterozygous for ABCA3 mutations. The first is the common mutation p.Glu292Val, which is found in heterozygous form with a frequency of <1% [8] and has been previously reported to be associated with mild lung disease. The second has not yet been described but is expected to be a disease-causing mutation as it introduces a premature termination codon, likely to be associated with markedly reduced mRNA levels due to nonsense-mediated degradation. Such a “null” allele precludes any functional ABCA3 from being made resulting in abnormal lamellar bodies, but should be less deleterious in combination with the mild mutation p.Glu292Val. Interactions with variants in other genes and/or with external factors such as viral or bacterial infections, as observed in our case, may also influence the observed phenotype [9].

The phenotype of our patient is very similar to that observed in the case reported by Cottin et al. [3] carrying SFTPC mutations. Our patient is a nonsmoker and the emphysematous lesions were voluminous and localised, mostly in the upper lobes, whereas asymmetric fibrosis lesions were predominant in the lower lobes.

There is no specific treatment for CPFE syndrome. Supported immunosuppressive therapy was not indicated in this case without evidence of active inflammation. Improvement of severe interstitial lung disease in a young patient with ABCA3 deficiency has been reported after treatment with azithromycin, an azalide macrolide antibiotic characterised by a nitrogen in the macrolide ring [10]. Although, there is no evidence of efficacy of azithromycin in CPFE, the worsening of our patient’s respiratory status together with the safety of this drug incited us to initiate this treatment in our patient.

To our knowledge, this is the first report of a phenotype of CPFE syndrome in an adult patient carrying mutations of the ABCA3 gene. Although further studies are needed to confirm the role of surfactant metabolism in CPFE, this result suggests that this syndrome may have an underlying genetic predisposition.

Footnotes

  • Support statement: This work was supported by INSERM (P. Fanen, R. Epaud and C. Delestrain), Assistance Publique-Hôpitaux de Paris (A. Tazi) and the Société de Pneumologie de Langue Française (C. Delestrain). ABCA3 gene analysis technic was designed and initiated for Surfactant Disorders and Chronic Lung Disease (APSE; ClinicalTrials.gov identifier NCT00783978) (R. Epaud and M. Louha).

  • Conflict of interest: None declared.

  • Received August 19, 2013.
  • Accepted September 21, 2013.
  • ©ERS 2014

References

  1. ↵
    1. Deutsch GH,
    2. Young LR,
    3. Deterding RR,
    4. et al
    . Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med 2007; 176: 1120–1128.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Cottin V,
    2. Nunes H,
    3. Brillet PY,
    4. et al
    . Combined pulmonary fibrosis and emphysema: a distinct under recognised entity. Eur Respir J 2005; 26: 586–593.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Cottin V,
    2. Reix P,
    3. Khouatra C,
    4. et al
    . Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax 2011; 66: 918–919.
    OpenUrlFREE Full Text
  4. ↵
    1. Flamein F,
    2. Riffault L,
    3. Muselet-Charlier C,
    4. et al
    . Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children. Hum Mol Genet 2011; 21: 765–775.
    OpenUrlPubMedWeb of Science
  5. ↵
    1. Cheong N,
    2. Madesh M,
    3. Gonzales LW,
    4. et al
    . Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J Biol Chem 2006; 281: 9791–9800.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Matsumura Y,
    2. Ban N,
    3. Ueda K,
    4. et al
    . Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency. J Biol Chem 2006; 281: 34503–34514.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Matsumura Y,
    2. Ban N,
    3. Inagaki N
    . Aberrant catalytic cycle and impaired lipid transport into intracellular vesicles in ABCA3 mutants associated with nonfatal pediatric interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2008; 295: L698–L707.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Wambach JA,
    2. Wegner DJ,
    3. Depass K,
    4. et al
    . Single ABCA3 mutations increase risk for neonatal respiratory distress syndrome. Pediatrics;130: e1575–e1582.
  9. ↵
    1. Bullard JE,
    2. Nogee LM
    . Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation. Pediatr Res 2007; 62: 176–179.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Thouvenin G,
    2. Nathan N,
    3. Epaud R,
    4. et al
    . Diffuse parenchymal lung disease caused by surfactant deficiency: dramatic improvement by azithromycin. BMJ Case Rep 2013 [in press DOI: 10.1136/bcr-2013-009988].
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 43 Issue 2 Table of Contents
European Respiratory Journal: 43 (2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations
Ralph Epaud, Céline Delestrain, Malek Louha, Stéphanie Simon, Pascale Fanen, Abdellatif Tazi
European Respiratory Journal Feb 2014, 43 (2) 638-641; DOI: 10.1183/09031936.00145213

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations
Ralph Epaud, Céline Delestrain, Malek Louha, Stéphanie Simon, Pascale Fanen, Abdellatif Tazi
European Respiratory Journal Feb 2014, 43 (2) 638-641; DOI: 10.1183/09031936.00145213
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Research letters

  • Characteristics of individuals with AATD from European countries
  • CFTR modulators and platelet activation in blood of COVID-19 patients
  • Implications of new ERS/ATS standards on lung function test interpretation
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society